Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Hua Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4552-0785; OpenAlex author ID A5050284408. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 7

  1. CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. Co-author DOI 10.1002/adhm.202500546↗
  2. [A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China]. Co-author DOI 10.3760/cma.j.cn112152-20231223-00383↗
  3. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2023.09.010↗
  4. The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction. Co-author DOI 10.1002/cam4.1988↗
  5. A Systematic Inflammation-based Model in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.30561↗
  6. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and rea… Last author DOI 10.1002/cam4.1573↗
  7. Expression of c-Myc and Fas correlates with perineural invasion of pancreatic cancer. First author PMID 22670178↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zonghai Li · 2 shared papers, 2023–2025 · strength 0.44
  2. Yaru Zhao · 1 shared paper, 2025 · strength 0.27
  3. Yue Qing · 1 shared paper, 2025 · strength 0.27
  4. Christopher Heeschen · 1 shared paper, 2025 · strength 0.27
  5. Kequn Xu · 3 shared papers, 2018–2019 · strength 0.26
  6. Junjie Hang · 3 shared papers, 2018–2019 · strength 0.26
  7. Lixia Wu · 3 shared papers, 2018–2019 · strength 0.26
  8. Xuguang Yang · 2 shared papers, 2019 · strength 0.18
  9. Hanyu Zhou · 2 shared papers, 2019 · strength 0.18
  10. Ruixin Sun · 1 shared paper, 2023 · strength 0.17
  11. Yifan Liu · 1 shared paper, 2023 · strength 0.17
  12. Huizi Sha · 1 shared paper, 2024 · strength 0.15
  13. Juan Du · 1 shared paper, 2024 · strength 0.15
  14. Xin Qiu · 1 shared paper, 2024 · strength 0.15
  15. Jun Wu · 1 shared paper, 2024 · strength 0.15
  16. Qiao-Li Wang · 1 shared paper, 2024 · strength 0.15
  17. B R Liu · 1 shared paper, 2024 · strength 0.15
  18. Siyuan Zhou · 1 shared paper, 2019 · strength 0.09
  19. Junjie Huang · 1 shared paper, 2019 · strength 0.09
  20. Yuli Lin · 1 shared paper, 2019 · strength 0.09
  21. Chengzhi He · 1 shared paper, 2012 · strength 0.03
  22. Changqing Yang · 1 shared paper, 2012 · strength 0.03
  23. Hengjun Gao · 1 shared paper, 2012 · strength 0.03
  24. Haihui Sheng · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.